Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

With Genetic Tests, Informed Consent Enters Psychosocial Realm

August 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 8
Volume 6
Issue 8

NEW ORLEANS--Informed consent has historically focused on physical risks, but genetic testing will move informed consent into psychosocial areas, Karen Rothenberg, JD, MPA, Marjorie Cook Professor of Law, University of Maryland School of Law, said at the 21st annual meeting of the American Society of Preventive Oncology (ASPO).

NEW ORLEANS--Informed consent has historically focused on physical risks,but genetic testing will move informed consent into psychosocial areas,Karen Rothenberg, JD, MPA, Marjorie Cook Professor of Law, University ofMaryland School of Law, said at the 21st annual meeting of the AmericanSociety of Preventive Oncology (ASPO).

With genetic testing, the informed consent process will need to addresssuch psychosocial risks as changes in self- image, altered family relationships,and possible stigmatization,

Patients must be told the potential benefits of genetic testing butalso the uncertainties, she said. For example, for many genetic tests forcancer, the true predictive value is unknown, the risk for misinterpretationis great, the effectiveness of prevention and intervention has not beensatisfactorily validated in trials, and the impact of testing on changesin health behavior is unknown.

Physicians must inform their patients that the legal protection of testresults is not uniform at this point, said Prof. Rothenberg, who is alsodirector of the Law and Health Care Program at the University of Maryland.

She said that about a dozen states prohibit health insurers from requestingthe results of genetic testing, from making coverage conditional on genetictesting, or from considering genetic testing in setting rates. Another20 states have laws pending.

"The catch is that except for a few states, most laws only protectthe genetic test result, not genetic information, such as might be obtainedfrom the family history in the medical record," she stressed.

In addition, states cannot regulate self-funded insurance plans, whichconstitute about half of all employee-provided insurance, Prof. Rothenbergsaid. The Health Insurance Portability and Accountability Act of 1996,also called the Kassenbaum/Kennedy law, provides some protection. However,it cannot prohibit insurers from requesting disclosure of genetic information,increasing rates for patients with certain conditions or findings, or excludingfrom coverage all patients with certain conditions.

Few actual protections exist in the workplace, either, since again mostrestrictions apply to genetic test results, not genetic information. Employersare generally not prohibited from requesting medical releases, and theycan legally attempt to obtain access to information, she said.

Issues of Family Privacy

The area of family privacy is especially controversial now. Issues includethe right of the patient and other family members to know or not know testresults, the individual's responsibility to share information with familymembers, reproductive decision making, and genetic testing of children.

"In the informed consent process, there needs to be discussionabout family sharing of information," Professor Rothenberg said. "Andpeople need to recognize that having genetic information can change theirresponsibilities, obligations, even rights."

Articles in this issue

Two-Step Approach Urged to Avoid High Tech, Wild Death
Health Insurance Premiums Tax Proposed
ODAC Votes Yes on Taxol for Kaposi's Sarcoma
Five Principles Help Resolve Ethical Dilemmas in Care
Ovarian Cancer Survivors Form National Coalition
Photodynamic Therapy Used in Nonmelanoma Skin Cancer
Increased Numbers of Nevi Can Predict Risk of Melanoma
With Genetic Tests, Informed Consent Enters Psychosocial Realm
Cryoablation May Have Limited Role in Prostate Cancer Treatment
Americans Not Convinced of Value of Watchful Waiting
Breast and Arm Sensations Are Common After Breast Surgery
Molecular Markers Are Used as Therapeutic Targets in Head & Neck Cancer: Three Studies
Urologists Urged to Get on Board With Prostate Brachytherapy
Fatigue in Breast Cancer Underrecognized, Particularly in Postmenopausal Women
Hereditary Prostate Cancer Appears More Aggressive
Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content
Advertisement

acute lymphoblastic leukemia

Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL

Ariana Pelosci
December 7th 2025
Article

Clinical efficacy and response rates were increased with blinatumomab/ponatinib vs chemotherapy/imatinib for patients with Ph+ ALL.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


Investigators reported fewer dose reductions due to treatment-emergent adverse effects with pirtobrutinib vs ibrutinib in the phase 3 BRUIN CLL-314 trial.

Noninferior Responses Occur With Pirtobrutinib vs Ibrutinib in CLL

Jason M. Broderick
December 7th 2025
Article

Investigators reported fewer dose reductions due to treatment-emergent adverse effects with pirtobrutinib vs ibrutinib in the phase 3 BRUIN CLL-314 trial.


Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.


Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Gina Mauro
December 7th 2025
Article

The phase 3 EPCORE FL-1 trial showed that adding epcoritamab to R2 delivered superior PFS and response rates for patients with relapsed/refractory FL vs R2 alone.


The Intricacies of Bispecific Antibodies in Multiple Myeloma

The Intricacies of Bispecific Antibodies in Multiple Myeloma

ONCOLOGY Staff
December 7th 2025
Article

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.

Related Content
Advertisement

acute lymphoblastic leukemia

Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL

Ariana Pelosci
December 7th 2025
Article

Clinical efficacy and response rates were increased with blinatumomab/ponatinib vs chemotherapy/imatinib for patients with Ph+ ALL.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


Investigators reported fewer dose reductions due to treatment-emergent adverse effects with pirtobrutinib vs ibrutinib in the phase 3 BRUIN CLL-314 trial.

Noninferior Responses Occur With Pirtobrutinib vs Ibrutinib in CLL

Jason M. Broderick
December 7th 2025
Article

Investigators reported fewer dose reductions due to treatment-emergent adverse effects with pirtobrutinib vs ibrutinib in the phase 3 BRUIN CLL-314 trial.


Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.


Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Gina Mauro
December 7th 2025
Article

The phase 3 EPCORE FL-1 trial showed that adding epcoritamab to R2 delivered superior PFS and response rates for patients with relapsed/refractory FL vs R2 alone.


The Intricacies of Bispecific Antibodies in Multiple Myeloma

The Intricacies of Bispecific Antibodies in Multiple Myeloma

ONCOLOGY Staff
December 7th 2025
Article

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.